Infant colic occurs in about 20 percent of infants younger than three months. This manifests itself in persistent and inconsolable crying, which is an enormous burden for the infants and parents. Currently, there are no products with scientifically proven efficacy. With BactoKind, ETH researcher Vanesa Rocha Martin wants to start here and develop a therapy with bacteria that can alleviate colic.
The project is based on a strong scientific background and data built on more than 12 years of research by ETH Zurich’s Food Biotechnology Laboratory and in collaboration with the Gastroenterology and Nutrition Unit at the Kinderspital Zürich (KISPI).
Read more about BactoKind in the ETH news.